BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 30243944)

  • 1. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
    Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
    Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of Doxorubicin and Ceramide in a Liposomal Formulation Enhances Cytotoxicity in Murine B16BL6 Melanoma Cell Lines.
    Chen L; Alrbyawi H; Poudel I; Arnold RD; Babu RJ
    AAPS PharmSciTech; 2019 Feb; 20(3):99. PubMed ID: 30719596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ethylene glycol)-induced and temperature-dependent phase separation in fluid binary phospholipid membranes.
    Lehtonen JY; Kinnunen PK
    Biophys J; 1995 Feb; 68(2):525-35. PubMed ID: 7696506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof.
    Levacheva I; Samsonova O; Tazina E; Beck-Broichsitter M; Levachev S; Strehlow B; Baryshnikova M; Oborotova N; Baryshnikov A; Bakowsky U
    Colloids Surf B Biointerfaces; 2014 Sep; 121():248-56. PubMed ID: 25001189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
    Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
    J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
    Krishna R; Mayer LD
    Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sterically stabilized liposomes production using staggered herringbone micromixer: Effect of lipid composition and PEG-lipid content.
    Cheung CCL; Al-Jamal WT
    Int J Pharm; 2019 Jul; 566():687-696. PubMed ID: 31212051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
    Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential administration of PEG-Span 80 niosome enhances anti-tumor effect of doxorubicin-containing PEG liposome.
    Minamisakamoto T; Nishiguchi S; Hashimoto K; Ogawara KI; Maruyama M; Higaki K
    Eur J Pharm Biopharm; 2021 Dec; 169():20-28. PubMed ID: 34461216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microfluidic-assisted fabrication of phosphatidylcholine-based liposomes for controlled drug delivery of chemotherapeutics.
    Gkionis L; Aojula H; Harris LK; Tirella A
    Int J Pharm; 2021 Jul; 604():120711. PubMed ID: 34015381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU).
    Park SM; Kim MS; Park SJ; Park ES; Choi KS; Kim YS; Kim HR
    J Control Release; 2013 Sep; 170(3):373-9. PubMed ID: 23770213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
    Krishna R; St-Louis M; Mayer LD
    Int J Cancer; 2000 Jan; 85(1):131-41. PubMed ID: 10585596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome-wide elucidation of liposomal formulations for anticancer drug delivery.
    Li Y; Wang M; Huang BW; Ping Y; You J; Gao JQ
    Int J Nanomedicine; 2017; 12():8557-8572. PubMed ID: 29238192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exhausting tumor associated macrophages with sialic acid-polyethyleneimine-cholesterol modified liposomal doxorubicin for enhancing sarcoma chemotherapy.
    Zheng H; Li J; Wang M; Luo X; Qiu Q; Hu L; Li C; Song Y; Deng Y
    Int J Pharm; 2019 Mar; 558():187-200. PubMed ID: 30654062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.